{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:01:46Z","timestamp":1791943306489,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01182-9","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:04:19Z","timestamp":1730977459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review"],"prefix":"10.1038","volume":"14","author":[{"given":"Can","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-4395","authenticated-orcid":false,"given":"Shenxian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1182_CR1","doi-asserted-by":"publisher","first-page":"E348","DOI":"10.1002\/ajh.24447","volume":"91","author":"JC Yui","year":"2016","unstructured":"Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D\u2019Agati VD, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016;91:E348\u201352.","journal-title":"Am J Hematol"},{"key":"1182_CR2","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1002\/ajh.25832","volume":"95","author":"MN Nguyen","year":"2020","unstructured":"Nguyen MN, Nayernama A, Jones SC, Kanapuru B, Gormley N, Waldron PE. Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature. Am J Hematol. 2020;95:E218\u2013e22.","journal-title":"Am J Hematol"},{"key":"1182_CR3","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl J Med. 2005;352:2487\u201398.","journal-title":"N. Engl J Med"},{"key":"1182_CR4","doi-asserted-by":"crossref","unstructured":"Ponraj R, Bryant A, Dunlop L, Range H, Cobrador C, Ling S, et al. Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA. Blood Cancer J. 2023;13:113.","DOI":"10.1038\/s41408-023-00885-9"},{"key":"1182_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.26147","volume":"96","author":"CP Venner","year":"2021","unstructured":"Venner CP, LeBlanc R, Sandhu I, White D, Belch AR, Reece DE, et al. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed\/refractory multiple myeloma: Final results from the MCRN-003\/MYX.1 single arm phase II trial. Am J Hematol. 2021;96:552\u201360.","journal-title":"Am J Hematol"},{"key":"1182_CR6","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/S2352-3026(22)00350-7","volume":"10","author":"K Yong","year":"2023","unstructured":"Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, et al. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib\u2013cyclophosphamide\u2013dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Lancet Haematol. 2023;10:e93\u2013e106.","journal-title":"Lancet Haematol"},{"key":"1182_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3324\/haematol.2014.119735","volume":"100","author":"JG Berdeja","year":"2015","unstructured":"Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, et al. Phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed\/refractory multiple myeloma. Haematologica. 2015;100:670\u20136.","journal-title":"Haematologica"},{"key":"1182_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12185-020-03013-6","volume":"113","author":"N Takezako","year":"2021","unstructured":"Takezako N, Shibayama H, Handa H, Hagiwara S, Ozaki S, Suzuki K, et al. Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR. Int J Hematol. 2021;113:219\u201330.","journal-title":"Int J Hematol"},{"key":"1182_CR9","doi-asserted-by":"crossref","unstructured":"Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Blood Cancer J. 2021;11:150.","DOI":"10.1038\/s41408-021-00544-x"},{"key":"1182_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000519687","volume":"100","author":"S Nakao","year":"2022","unstructured":"Nakao S, Uchida M, Satoki A, Okamoto K, Uesawa Y, Shimizu T. Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database. Oncology. 2022;100:60\u20134.","journal-title":"Oncology"},{"key":"1182_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.62","volume":"6","author":"Y Chen","year":"2016","unstructured":"Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, et al. Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer J. 2016;6:e450.","journal-title":"Blood Cancer J"},{"key":"1182_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ejh.13401","volume":"104","author":"P Kozlowski","year":"2020","unstructured":"Kozlowski P, Kameran Behnam K, Uggla B, \u00c5str\u00f6m M. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. Eur J Haematol. 2020;104:588\u201393.","journal-title":"Eur J Haematol"},{"key":"1182_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/10428194.2022.2057485","volume":"63","author":"T Terao","year":"2022","unstructured":"Terao T, Tsushima T, Miura D, Ikeda D, Fukumoto A, Kuzume A, et al. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review. Leuk Lymphoma. 2022;63:1102\u201310.","journal-title":"Leuk Lymphoma"},{"key":"1182_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ejh.13671","volume":"107","author":"BE Monteith","year":"2021","unstructured":"Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, et al. A descriptive cost-analysis of MYX.1\/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. Eur J Haematol. 2021;107:333\u201342.","journal-title":"Eur J Haematol"},{"key":"1182_CR15","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"1182_CR16","first-page":"1","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, et al. Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review. Cardio Oncol. 2023;5:1\u201321.","journal-title":"Cardio Oncol"},{"key":"1182_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.yjmcc.2022.10.002","volume":"173","author":"C Tu","year":"2022","unstructured":"Tu C, Liu Y, Williams DR, Wu JC. A transcriptomic atlas of drug-induced endothelial dysfunction in human endothelial cells. J Mol Cell Cardiol. 2022;173:115\u20137.","journal-title":"J Mol Cell Cardiol"},{"key":"1182_CR18","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41375-021-01141-4","volume":"35","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Laina A, Georgiopoulos G, Gavriatopoulou M, Papanagnou E-D, Eleutherakis-Papaiakovou E, et al. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia. 2021;35:1418\u201327.","journal-title":"Leukemia"},{"key":"1182_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bjh.16796","volume":"193","author":"M Blasco","year":"2021","unstructured":"Blasco M, Mart\u00ednez-Roca A, Rodr\u00edguez-Lobato LG, Garcia-Herrera A, Rosi\u00f1ol L, Castro P, et al. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol. 2021;193:181\u20137.","journal-title":"Br J Haematol"},{"key":"1182_CR20","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3109\/10428190903275586","volume":"50","author":"SA Kumar","year":"2009","unstructured":"Kumar SA, Hu X, Brown M, Kuschak B, Hernandez TA, Johnston JB, et al. Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression. Leuk lymphoma. 2009;50:2038\u201348.","journal-title":"Leuk lymphoma"},{"key":"1182_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","volume":"19","author":"K Holmes","year":"2007","unstructured":"Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19:2003\u201312.","journal-title":"Cell Signal"},{"key":"1182_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","volume":"127","author":"LS Keir","year":"2017","unstructured":"Keir LS, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E, et al. VEGF regulates local inhibitory complement proteins in the eye and kidney. J Clin Investig. 2017;127:199\u2013214.","journal-title":"J Clin Investig"},{"key":"1182_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00467-010-1637-4","volume":"26","author":"L Keir","year":"2011","unstructured":"Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol. 2011;26:523\u201333.","journal-title":"Pediatr Nephrol"},{"key":"1182_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bbamcr.2012.03.001","volume":"1823","author":"TM Kitzler","year":"2012","unstructured":"Kitzler TM, Papillon J, Guillemette J, Wing SS, Cybulsky AV. Complement modulates the function of the ubiquitin\u2013proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells. Biochim Biophys Acta Mol Cell Res. 2012;1823:1007\u201316.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1182_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-4614-3209-8_31","volume":"801","author":"Z Liu","year":"2014","unstructured":"Liu Z, Qin T, Zhou J, Taylor A, Sparrow JR, Shang F. Impairment of the ubiquitin-proteasome pathway in RPE alters the expression of inflammation related genes. Adv Exp Med Biol. 2014;801:237\u201350.","journal-title":"Adv Exp Med Biol"},{"key":"1182_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756941","volume":"12","author":"T Walhelm","year":"2021","unstructured":"Walhelm T, Gunnarsson I, Heijke R, Leonard D, Trysberg E, Eriksson P, et al. Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: a nationwide study. Front Immunol. 2021;12:756941.","journal-title":"Front Immunol"},{"key":"1182_CR27","doi-asserted-by":"crossref","unstructured":"Gavriilaki E, Dalampira D, Theodorakakou F, Liacos CI, Kanellias N, Eleutherakis-Papaiakovou E, et al. Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. J Clin Med. 2022;11:3355.","DOI":"10.3390\/jcm11123355"},{"key":"1182_CR28","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","volume":"2","author":"AJ Portuguese","year":"2018","unstructured":"Portuguese AJ, Lipe B. Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. Blood Adv. 2018;2:3443\u20136.","journal-title":"Blood Adv"},{"key":"1182_CR29","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.clml.2020.01.016","volume":"20","author":"D Bhutani","year":"2020","unstructured":"Bhutani D, Assal A, Mapara MY, Prinzing S, Lentzsch S. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Clin Lymphoma Myeloma Leuk. 2020;20:e155\u2013e7.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1182_CR30","volume":"2016","author":"J Van Keer","year":"2016","unstructured":"Van Keer J, Delforge M, Dierickx D, Peerlinck K, Lerut E, Sprangers B. Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma. Case Rep Hematol. 2016;2016:6020691.","journal-title":"Case Rep Hematol"},{"key":"1182_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00802-0","volume":"13","author":"M Moscvin","year":"2023","unstructured":"Moscvin M, Liacos CI, Chen T, Theodorakakou F, Fotiou D, Hossain S, et al. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer J. 2023;13:31.","journal-title":"Blood Cancer J"},{"key":"1182_CR32","doi-asserted-by":"crossref","unstructured":"Mehta N, Saxena A, Niesvizky R. Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep. 2012;2012:bcr2012006461.","DOI":"10.1136\/bcr-2012-006461"},{"key":"1182_CR33","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.4081\/hr.2012.e13","volume":"4","author":"U Salmenniemi","year":"2012","unstructured":"Salmenniemi U, Remes K. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep. 2012;4:e13.","journal-title":"Hematol Rep"},{"key":"1182_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/2399369319894343","volume":"4","author":"N Moreira Fonseca","year":"2020","unstructured":"Moreira Fonseca N, Cardoso F, Monteiro M, G\u00f3is M, Sousa H, Fidalgo T, et al. A case of bortezomib-associated thrombotic microangiopathy in a multiple myeloma patient. J Onco Nephrol. 2020;4:46\u201351.","journal-title":"J Onco Nephrol"},{"key":"1182_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ajh.20648","volume":"81","author":"H Nakamae","year":"2006","unstructured":"Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, et al. Risk factor analysis for thrombotic microangiopathy after reduced\u2010intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2006;81:525\u201331.","journal-title":"Am J Hematol"},{"key":"1182_CR36","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.17377","volume":"193","author":"M Camilleri","year":"2021","unstructured":"Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, et al. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol. 2021;193:750\u201360.","journal-title":"Br J Haematol"},{"key":"1182_CR37","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.mayocp.2016.05.015","volume":"91","author":"RS Go","year":"2016","unstructured":"Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS. et al. Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc. 2016;91:1189\u2013211.","journal-title":"Mayo Clin Proc"},{"key":"1182_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1053\/ajkd.1998.v32.pm9708619","volume":"32","author":"J Palmisano","year":"1998","unstructured":"Palmisano J, Agraharkar M, Kaplan AA. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J kidney Dis. 1998;32:314\u20137.","journal-title":"Am J kidney Dis"},{"key":"1182_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","volume":"44","author":"JN George","year":"2004","unstructured":"George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura\u2010hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004;44:294\u2013304.","journal-title":"Transfusion"},{"key":"1182_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1088031","volume":"13","author":"T Mazzierli","year":"2022","unstructured":"Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management. Front Pharm. 2022;13:1088031.","journal-title":"Front Pharm"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01182-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01182-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01182-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:04:55Z","timestamp":1730977495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01182-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01182-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}